Abstract
Subcortical arteriosclerotic encephalopathy (SAE) can affect the nigrostriatal system and presumably cause vascular parkinsonism (VP). However, in patients with SAE, the differentiation of VP from idiopathic Parkinson’s disease (IPS) is challenging. The aim of the present study was to examine the striatal dopamine transporter (DAT) density in patients with parkinsonism and SAE. Fifteen consecutive patients with parkinsonian symptoms displayed SAE, as detected by magnetic resonance imaging (MRI). Fifteen retrospectively chosen, matched patients with diagnosis of IPS without any abnormalities in MRI served as a reference group. DAT SPECT was performed using the tracer 123I-FP-CIT. Scans were acquired on a triple-head SPECT system (Multispect 3, Siemens) and analysed using the investigator-independent BRASS™ software (HERMES). In the SAE group, a DAT deficit was observed in 9/15 patients. In contrast, all patients from the IPS group showed a reduced DAT binding (p = 0.008). The specific binding ratios (BR) of putamen contralateral to the side of the more affected limb versus occipital lobe were in trend higher in patients with SAE versus patients in the IPS-group (p = 0.053). Indices for putaminal asymmetry (p = 0.036) and asymmetry caudate-to-putamen (p = 0.026) as well as the ratio caudate-to-putamen (p = 0.048) were significantly higher in IPS patients having no SAE. DAT deficit was less pronounced in patients with SAE and parkinsonism than in patients with IPS without any abnormalities in the MRI. A potential role of DAT SPECT in the differential diagnosis of VP and IPS requires more assessments within prospective studies.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Antonini A, Vitale C, Barone P et al (2012) The relationship between cerebral vascular disease and parkinsonism: the VADO study. Parkinsonism Relat Disord 18(6):775–780
Bain PG (2009) Dystonic tremor presenting as parkinsonism: long-term follow-up of SWEDDs. Neurology 72(16):1443–1445
Boecker H, Weindl A, Leenders K et al (1996) Secondary parkinsonism due to focal substantia nigra lesions: a PET study with [18F]FDG and [18F]fluorodopa. Acta Neurol Scand 93(6):387–392
Bohnen NI, Albin RL (2011) White matter lesions in Parkinson disease. Nat Rev Neurol 7(4):229–236
Bower JH, Maraganore DM, McDonnell SK et al (1999) Incidence and distribution of parkinsonism in Olmsted County, Minnesota, 1976–1990. Neurology 52(6):1214–1220
Brucke T, Asenbaum S, Pirker W et al (1997) Measurement of the dopaminergic degeneration in Parkinson’s disease with [123I] beta-CIT and SPECT. Correlation with clinical findings and comparison with multiple system atrophy and progressive supranuclear palsy. J Neural Transm Suppl 50:9–24
Chang CM, Yu YL, Ng HK et al (1992) Vascular pseudoparkinsonism. Acta Neurol Scand 86(6):588–592
Critchley M (1929) Arteriosclerotic Parkinsonism. Brain 52(1):23–83
de Rijk MC, Tzourio C, Breteler MM et al (1997) Prevalence of parkinsonism and Parkinson’s disease in Europe: the EUROPARKINSON Collaborative Study. European Community Concerted Action on the Epidemiology of Parkinson’s disease. J Neurol Neurosurg Psychiatry 62(1):10–15
Demirkiran M, Bozdemir H, Sarica Y (2001) Vascular parkinsonism: a distinct, heterogeneous clinical entity. Acta Neurol Scand 104(2):63–67
Ebersbach G, Poewe W (2006) Vascular parkinsonian syndrome. Nervenarzt 77(2):139–144, 146–137
Fahn S (2006) A new look at levodopa based on the ELLDOPA study. J Neural Transm Suppl 70:419–426
Foltynie T, Barker R, Brayne C (2002) Vascular parkinsonism: a review of the precision and frequency of the diagnosis. Neuroepidemiology 21(1):1–7
Gerschlager W, Bencsits G, Pirker W et al (2002) [123I]beta-CIT SPECT distinguishes vascular parkinsonism from Parkinson’s disease. Mov Disord 17(3):518–523
Ghebremedhin E, Rosenberger A, Rub U et al (2010) Inverse relationship between cerebrovascular lesions and severity of Lewy body pathology in patients with Lewy body diseases. J Neuropathol Exp Neurol 69(5):442–448
Hesse S, Oehlwein C, Barthel H et al (2006) Possible impact of dopamine SPECT on decision-making for drug treatment in Parkinsonian syndrome. J Neural Transm 113(9):1177–1190
Hughes AJ, Daniel SE, Kilford L et al (1992) Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 55(3):181–184
Kalra S, Grosset DG, Benamer HT (2010) Differentiating vascular parkinsonism from idiopathic Parkinson’s disease: a systematic review. Mov Disord 25(2):149–156
Lorberboym M, Djaldetti R, Melamed E et al (2004) 123I-FP-CIT SPECT imaging of dopamine transporters in patients with cerebrovascular disease and clinical diagnosis of vascular parkinsonism. J Nucl Med 45(10):1688–1693
Marek KL, Seibyl JP, Zoghbi SS et al (1996) [123I] beta-CIT/SPECT imaging demonstrates bilateral loss of dopamine transporters in hemi-Parkinson’s disease. Neurology 46(1):231–237
Marek K, Jennings D, Seibyl J (2003) Dopamine agonists and Parkinson’s disease progression: what can we learn from neuroimaging studies. Ann Neurol 53(Suppl 3):S160–S166 (discussion S166–S169)
Mark MH, Sage JI, Walters AS et al (1995) Binswanger’s disease presenting as levodopa-responsive parkinsonism: clinicopathologic study of three cases. Mov Disord 10(4):450–454
Nakane M, Teraoka A, Asato R et al (1992) Degeneration of the ipsilateral substantia nigra following cerebral infarction in the striatum. Stroke 23(3):328–332
Nakayama H, Tamura A, Kanazawa I et al (1990) Time-sequential change of amino acid neurotransmitters—GABA, aspartate and glutamate—in the rat basal ganglia following middle cerebral artery occlusion. Neurol Res 12(4):231–235
Peralta C, Werner P, Holl B et al (2004) Parkinsonism following striatal infarcts: incidence in a prospective stroke unit cohort. J Neural Transm 111(10–11):1473–1483
Piccini P, Pavese N, Canapicchi R et al (1995) White matter hyperintensities in Parkinson’s disease. Clinical correlations. Arch Neurol 52(2):191–194
Plotkin M, Amthauer H, Klaffke S et al (2005a) Combined 123I-FP-CIT and 123I-IBZM SPECT for the diagnosis of parkinsonian syndromes: study on 72 patients. J Neural Transm 112(5):677–692
Plotkin M, Amthauer H, Quill S et al (2005b) Imaging of dopamine transporters and D2 receptors in vascular parkinsonism: a report of four cases. J Neural Transm 112(10):1355–1361
Reitz C, Trenkwalder C, Kretzschmar K et al (2006) Relation of cerebral small-vessel disease and brain atrophy to mild Parkinsonism in the elderly. Mov Disord 21(11):1914–1919
Santangelo G, Vitale C, Trojano L et al (2010) Differential neuropsychological profiles in Parkinsonian patients with or without vascular lesions. Mov Disord 25(1):50–56
Seibyl JP, Marek KL, Quinlan D et al (1995) Decreased single-photon emission computed tomographic [123I]beta-CIT striatal uptake correlates with symptom severity in Parkinson’s disease. Ann Neurol 38(4):589–598
Sixel-Doring F, Liepe K, Mollenhauer B et al (2011) The role of 123I-FP-CIT-SPECT in the differential diagnosis of Parkinson and tremor syndromes: a critical assessment of 125 cases. J Neurol 258(12):2147–2154
Thanvi B, Lo N, Robinson T (2005) Vascular parkinsonism—an important cause of parkinsonism in older people. Age Ageing 34(2):114–119
Thompson PD, Marsden CD (1987) Gait disorder of subcortical arteriosclerotic encephalopathy: Binswanger’s disease. Mov Disord 2(1):1–8
Tohgi H, Takahashi S, Abe T et al (2001) Symptomatic characteristics of parkinsonism and the width of substantia nigra pars compacta on MRI according to ischemic changes in the putamen and cerebral white matter: implications for the diagnosis of vascular parkinsonism. Eur Neurol 46(1):1–10
Trenkwalder C, Schwarz J, Gebhard J et al (1995) Starnberg trial on epidemiology of Parkinsonism and hypertension in the elderly. Prevalence of Parkinson’s disease and related disorders assessed by a door-to-door survey of inhabitants older than 65 years. Arch Neurol 52(10):1017–1022
Tzen KY, Lu CS, Yen TC et al (2001) Differential diagnosis of Parkinson’s disease and vascular parkinsonism by (99m)Tc-TRODAT-1. J Nucl Med 42(3):408–413
van Zagten M, Lodder J, Kessels F (1998) Gait disorder and parkinsonian signs in patients with stroke related to small deep infarcts and white matter lesions. Mov Disord 13(1):89–95
Vlaar AM, de Nijs T, Kessels AG et al (2008) Diagnostic value of 123I-ioflupane and 123I-iodobenzamide SPECT scans in 248 patients with parkinsonian syndromes. Eur Neurol 59(5):258–266
Whone AL, Watts RL, Stoessl AJ et al (2003) Slower progression of Parkinson’s disease with ropinirole versus levodopa: the REAL-PET study. Ann Neurol 54(1):93–101
Winikates J, Jankovic J (1999) Clinical correlates of vascular parkinsonism. Arch Neurol 56(1):98–102
Zijlmans JC (2010) The role of imaging in the diagnosis of vascular parkinsonism. Neuroimaging Clin N Am 20(1):69–76
Zijlmans JC, Thijssen HO, Vogels OJ et al (1995) MRI in patients with suspected vascular parkinsonism. Neurology 45(12):2183–2188
Zijlmans JC, Daniel SE, Hughes AJ et al (2004) Clinicopathological investigation of vascular parkinsonism, including clinical criteria for diagnosis. Mov Disord 19(6):630–640
Zijlmans J, Evans A, Fontes F et al (2007) [123I] FP-CIT spect study in vascular parkinsonism and Parkinson’s disease. Mov Disord 22(9):1278–1285
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Funke, E., Kupsch, A., Buchert, R. et al. Impact of subcortical white matter lesions on dopamine transporter SPECT. J Neural Transm 120, 1053–1060 (2013). https://doi.org/10.1007/s00702-013-0977-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00702-013-0977-1